Befiradol is under clinical development by Neurolixis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Befiradol’s likelihood of approval (LoA) and phase transition for Drug-Induced Dyskinesia took place on 22 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Befiradol Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Befiradol overview

Befiradol (NLX-112, F-13640) is under development for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease, acute pain, tonic pain and depression. It is administered through oral route. It is a new chemical entity (NCE). The drug candidate acts by targeting serotonin 5-HT (1A) receptor. It was also under development for moderate to severe central neuropathic pain, diabetic neuropathic pain and cancer pain.

Neurolixis overview

Neurolixis is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. Its pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induced dyskinesia; and NLX-101 is a drug used for the treatment of breathing difficulties in Rett’s syndrome, a genetically-encoded orphan disorder. Neurolixis therapeutic focus include pre-clinical drug discovery and early clinical development of candidates targeting unmet needs in the field of neurological and neuropsychiatric illness. The company offers treatment solutions for human central nervous system disorders such as Parkinson’s disease, Rett syndrome, depression and schizophrenia. Neurolixis is headquartered in Dana Point, California, the US.

Quick View Befiradol LOA Data

Report Segments
  • Innovator
Drug Name
  • Befiradol
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Developers
  • Sponsor Company: Neurolixis
  • Originator: Laboratoires Pierre Fabre
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.